Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Disease Categories: (one of the following)
- AML, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease
- AML, age 51-60 years of age, in first or subsequent remission or relapsed/refractory disease
- AML with multilineage dysplasia
- ALL, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease
- ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease
- CML Beyond 2nd chronic phase or in blast crisis
- MDS; Includes World Health Organization classifications of refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS
- Myeloproliferative disorders; MDS with poor long-term survival including myeloid metaplasia and myelofibrosis
- High risk NHL in first remission
- Relapsed or refractory NHL
- HL beyond first remission
- Males and females of any ethnic background 2 - 60 years of age
- Karnofsky Performance Status ≥ 70% or Lansky performance status > 70% for patients < 16 years of age.
- Matched related donor identified: 6/6 HLA-A, B and DRB1
- Willingness to take oral medications during the transplantation period
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Prior myeloablative allogeneic or autologous HCT
- HIV infection
- Pregnant
- Lactating females
- Evidence of uncontrolled active infection
- Organ Dysfunction:
- Serum creatinine > 1.5 mg/dL or 24 hour creatinine clearance < 50 ml/min
- Direct bilirubin, ALT or AST > 2 x ULN
- In adults DLCO < 60% predicted and in children room air oxygen saturation < 92%
- In adults, left ventricular ejection fraction < 45% and in children, shortening fraction < 26%
- Fasting Cholesterol > 300 mg/dL or Triglycerides > 300 mg/dL while on lipid-lowering agents.
- Patients receiving investigational drugs unless cleared by the PI.
- Patients with prior malignancies except basal cell carcinoma or treated carcinoma in-situ.
- Cancer treated with curative intent > 5 years will be allowed.
- Cancer treated with curative intent ≤ 5 years will not be allowed with PI approval.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Regimen Treatment 1
For subjects 18-60 years old with lymphoma: (BCNU+ VP-16 +CY) BCNU 15 mg / kg (maximum dose 550 mg/m² actual body weight) on day -6.
VP 60 mg / kg on day 4 and CY 100 mg / kg on day -2.
Followed by Sirolimus and MMF as prophylaxis
|
Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
Other Names:
Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
Other Names:
15 mg/kg, IV
Other Names:
60 mg/kg, IV
Other Names:
For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
Other Names:
|
|
Experimental: Regimen Treatment 2
For subjects 18-50 years old with AML, ALL or CML: (VP-16 +CY+ FBI) Patients aged 18-50 years with AML, ALL or CML: FTBI 1320 cGy delivered in 11 120 cGy fractions over 4 days on days -8 through -5.
VP 60 mg / kg on day -4 and CY 60 mg / kg on day -2.
Followed by Sirolimus and MMF as prophylaxis
|
Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
Other Names:
Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
Other Names:
60 mg/kg, IV
Other Names:
For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
Other Names:
1320 cGy delivered in 11 120 cGy fractions over 4 day
Other Names:
|
|
Experimental: Regimen Treatment 3
For subjects 51-60 years with MDS, AML or ALL or 18-60 with MDS, secondary AML pr non-CML myeloproliferative disease: (BU+ VP-16 +CY) BU 1 mg/kg every 6 hours X 14 doses on days -9 through -6 with target concentration at steady state of X 800 ng / ml based on first dose pharmacokinetics.
VP 60 mg / kg on day -5 and CY 45 mg / kg per day -2 days on day -3 and day -2.
Followed by Sirolimus and MMF as prophylaxis
|
Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
Other Names:
Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
Other Names:
60 mg/kg, IV
Other Names:
For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
Other Names:
BU 1 mg/kg every 6hr x 4 doses, IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the incidence of grade II-IV acute GVHD with sirolimus and mycophenolate mofetil GVHD prophylaxis.
Time Frame: D+100 post-transplant
|
D+100 post-transplant
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Laura Johnston, Stanford University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Hematologic Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cyclophosphamide
- Etoposide
- Mycophenolic Acid
- Sirolimus
- Busulfan
- Carmustine
Other Study ID Numbers
Other Study ID Numbers
- IRB-06112
- 6112 (Other Identifier: Stanford IRB)
- 97168 (Other Identifier: Stanford University)
- BMT184 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.